Celltrion's Truxima, a biosimilar of Roche's Rituxan, has captured a 30-percent market share in Europe, Pulse reported Monday.
According to IQVIA, the market share of the therapy in the 18 European countries in which it is marketed reached 32 percent in June.
The market share in the UK, Germany, France, Italy and Spain in particular reached 34 percent.
The therapy was initially launched in the UK in April after gaining European approval in February.
To read more NewsPoints articles, click here.